Supplement GMP Documentation Better, But Still No. 2 On FDA Observation List – AHPA

FDA revisits about a third of supplement manufacturing sites, with two-thirds coming within three years, says AHPA. Chief information analyst Merle Zimmermann says FDA increased focus on recordkeeping has resulted in an improvement and fewer problems reported since 2015